NAMPT single-nucleotide polymorphism rs1319501 and visfatin/NAMPT affect nitric oxide formation, sFlt-1 and antihypertensive therapy response in preeclampsia (2021)
- Authors:
- USP affiliated authors: LACCHINI, RICCARDO - EERP ; CAVALLI, RICARDO DE CARVALHO - FMRP ; SANTOS, JOSE EDUARDO TANUS DOS - FMRP
- Unidades: EERP; FMRP
- DOI: 10.2217/pgs-2021-0006
- Subjects: FÁRMACOS (SISTEMA CARDIOVASCULAR); CITOCINAS; ÓXIDO NÍTRICO; POLIMORFISMO; PRÉ-ECLÂMPSIA
- Keywords: Antihypertensive agents; Genetic polymorphisms; Nicotinamide phosphoribosyltransferase; Nitric oxide; Pharmacogenetics; Preeclampsia; SFlt-1; Visfatin/NAMPT
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Source:
- Título do periódico: Pharmacogenomics
- ISSN: 1462-2416
- Volume/Número/Paginação/Ano: v. 22, n. 8, p. 451-464, 2021
- Este periódico é de assinatura
- Este artigo é de acesso aberto
- URL de acesso aberto
- Cor do Acesso Aberto: green
-
ABNT
PEREIRA, Daniela A. et al. NAMPT single-nucleotide polymorphism rs1319501 and visfatin/NAMPT affect nitric oxide formation, sFlt-1 and antihypertensive therapy response in preeclampsia. Pharmacogenomics, v. 22, n. 8, p. 451-464, 2021Tradução . . Disponível em: https://doi.org/10.2217/pgs-2021-0006. Acesso em: 19 abr. 2024. -
APA
Pereira, D. A., Sandrim, V. C., Palei, A. C., Amaral, L. M., Belo, V. A., Lacchini, R., et al. (2021). NAMPT single-nucleotide polymorphism rs1319501 and visfatin/NAMPT affect nitric oxide formation, sFlt-1 and antihypertensive therapy response in preeclampsia. Pharmacogenomics, 22( 8), 451-464. doi:10.2217/pgs-2021-0006 -
NLM
Pereira DA, Sandrim VC, Palei AC, Amaral LM, Belo VA, Lacchini R, Cavalli R de C, Tanus-Santos JE, Luizon MR. NAMPT single-nucleotide polymorphism rs1319501 and visfatin/NAMPT affect nitric oxide formation, sFlt-1 and antihypertensive therapy response in preeclampsia [Internet]. Pharmacogenomics. 2021 ; 22( 8): 451-464.[citado 2024 abr. 19 ] Available from: https://doi.org/10.2217/pgs-2021-0006 -
Vancouver
Pereira DA, Sandrim VC, Palei AC, Amaral LM, Belo VA, Lacchini R, Cavalli R de C, Tanus-Santos JE, Luizon MR. NAMPT single-nucleotide polymorphism rs1319501 and visfatin/NAMPT affect nitric oxide formation, sFlt-1 and antihypertensive therapy response in preeclampsia [Internet]. Pharmacogenomics. 2021 ; 22( 8): 451-464.[citado 2024 abr. 19 ] Available from: https://doi.org/10.2217/pgs-2021-0006 - Effects of matrix metalloproteinase (MMP)-2 polymorphisms on responsiveness to antihypertensive therapy of women with hypertensive disorders of pregnancy
- Tissue inhibitor of matrix metalloproteinase-1 polymorphism, plasma TIMP-1 levels, and antihypertensive therapy responsiveness in hypertensive disorders of pregnancy
- Interethnic differences in the distribution of matrix metalloproteinases genetic polymorphisms are consistent with interethnic differences in disease prevalence
- Increased activity of MMP-2 in hypertensive obese children is associated with hypoadiponectinemia
- Clinical and pharmacogenetic impact of endothelial nitric oxide synthase polymorphisms on cardiovascular diseases
- Circulating HO-1 levels are not associated with plasma sFLT-1 and GTn HMOX1 polymorphism in preeclampsia
- Matrix metalloproteinase (MMP)-2 genetic variants modify the circulating MMP-2 levels in end-stage kidney disease
- Endothelial nitric oxide synthase: from biochemistry and gene structure to clinical implications of NOS3 polymorphisms
- The effects of NAMPT haplotypes and metabolic risk factors on circulating visfatin/NAMPT levels in childhood obesity
- Matrix metalloproteinase-9 polymorphisms affect plasma MMP-9 levels and antihypertensive therapy responsiveness in hypertensive disorders of pregnancy
Informações sobre o DOI: 10.2217/pgs-2021-0006 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
